Introduction
Prostate cancer is the most common cancer in American men other than skin cancer. In the United States in the year 2003, it is estimated that about 220900 new cases of prostate cancer will be newly diagnosed, with about 28900 deaths from this disease. Multiple epidemiological studies have confirmed that prostate cancer occurs at a higher prevalence and with greater morbidity in African-American men than in most other populations. [1] [2] [3] [4] [5] The age-adjusted incidence rate of invasive prostate cancer for African-American men was 272.1 per 100 000 for the period from 1996 to 2000 6 compared to 163.3 per 100 000 in White males. Recently reported prostate cancer age-adjusted mortality rates between 1996 and 2000, are approximately two times worse among African-American than Caucasian men. 6 Agespecific mortality rates for prostate cancer are reportedly higher among African-American men compared to Caucasian men for all ages after age 40 y. 6 The reasons for these observations are still not known. Affected males from families with hereditary prostate cancer (HPC) account for 5-10% of all reported cases of prostate cancer in the United States and Europe. [7] [8] [9] It is against this background that the African-American Hereditary Prostate Cancer Study (AAHPC) was initiated to recruit African-American families to a hereditary prostate cancer study. This is the first large-scale study to describe the clinical characteristics of hereditary prostate cancer in affected African-American men from multiplex families. This elaborate multi-institutional network was designed to recruit African-American families that fulfill very stringent criteria for hereditary prostate cancer, exceeding those originally proposed by Carter et al.
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The AAHPC inclusion criteria were as follows: (a) African-American families with four or more members diagnosed with prostate cancer, (b) the combined age at diagnosis of all affected members in the family should average 65 y or less, (c) at least three affected members must donate a sample of blood for genotyping. These criteria differ from the original HPC definition proposed by Carter et al, 7, 10 in which the hereditary subgroup consisted of three successive generations with prostate cancer, a clustering of three or more affected individuals in a nuclear family and/or two relatives with early onset (less than 55 y) of prostate cancer. The details of the AAHPC network infrastructure and recruitment protocols have been previously reported. 3, 11 Informed consent was obtained on all participants. We present a descriptive report of the clinical characteristics of a sample of affected AAHPC family members.
Materials and methods
In the AAHPC study, age at diagnosis was available for 191 African-American men with prostate cancer; therefore, the age parameters were calculated with this denominator. Of these individuals, 154 had complete clinical data that were retrospectively reviewed from medical and pathological records. The clinical parameters of interest included age at diagnosis, serum prostate-specific antigen (PSA) levels, tumor stage and grade, and primary therapy (which was obtained from questionnaires and patient medical records). Stage and grade data were standardized using the 1997 TumorNode-Metastasis staging classification 12 (local tumor growth (T), spread to regional lymph nodes (N), and distant metastases (M)), together with the Gleason score. 13 Distant metastases (M þ ) and node-positive disease without the presence of metastases (N þ , Mo) were also recorded. Pathologic stages were available for prostatectomy cases only. The families were dichotomized into those with 4-6 affected men vs those with more than six affected. We chose this stratification because we expected that families with more than six affected men might have certain unusual characteristics, such as more aggressive disease. The number of affected men with prostate cancer per family was calculated for each group (4-6, 46), with subsequent evaluation of all clinical parameters according to this stratification. For statistical analysis, nonparametric Wilcoxon two-sample tests were performed to compare these two groups in terms of the continuous variables such as age at diagnosis and PSA levels. Tumor stage was classified as localized (T1-T2/No/Mo), locally advanced (T3-T4/ No/Mo), locally advanced disease with regional lymph nodes (N þ /Mo), or distant metastases (M þ ). Fisher's exact test (two-tailed) was used to compare 4-6 and 46 two groups with respect to clinical characteristics such as tumor stage, PSA level at diagnosis (o10, 10-20, 420 ng/ml) and Gleason score (2-6, 7-10).
Results
In all, 92 families with 346 affected men were recruited from multiple sites within the United States between 1998 and 2002. Age at diagnosis information was available on 191 affected men, but complete clinical data were available on 154 men. This extent of missing information occurred due to the difficulty of obtaining clinical data on relatives long deceased for whom adequate records were no longer available. Clinical characteristics and primary therapy are shown in Tables 1 and 2 9, 15 but the AAHPC study has the largest collection of AfricanAmerican HPC families ascertained through probands. Besides having many affected males, these families are also notable for early onset of disease, with a mean age at diagnosis of 61.0 y.
Following the Carter et al 10 categorization of prostate cancer into sporadic, familial, and hereditary subgroups, the clinical characteristics of HPC families, and how they differ from sporadic cases, have been the subject of considerable controversy in the literature. [16] [17] [18] [19] A review of the clinical characteristics of 74 North American HPC families potentially linked to the HPC1 locus on chromosome 1 demonstrated three distinct clinical characteristics, including earlier age of onset, higher grade tumors, and more advanced disease at diagnosis compared to agematched sporadic cases. 20 Bratt et al 21 recently reported earlier age of onset in Swedish HPC families compared to sporadic cases, but found no differences in clinical characteristics or survival between the two groups. Other reports have reported no differences between biological aggressiveness of hereditary prostate cancer and sporadic cases. Bauer et al 22 reviewed 474 radical prostatectomy patients, 78 of whom had at least one affected first-degree family member. The mean age at diagnosis for this radical prostatectomy series was 62 y. Bauer et al 22 found no differences in histologic grade, margin positive status, capsular penetration, or disease-free survival in patients with positive family history vs sporadic cases. Bova et al 17 reported similar findings. However, neither study 17, 22 reported the numbers of affected per family. Hence, these families may represent 'familial' cases vs 'hereditary' cases as defined by Carter et al. 10 Schleutker et al 18 reported late age of onset in Finnish HPC families linked to the HPCX susceptibility locus. The important findings from the current study include the considerably lower mean age at diagnosis of 61.0 y for all affected men in the AAHPC study, compared to the overall HPC family collections in the ICPCG. Additionally, the mean number of 5.5 cases per family exceeds the already stringent criteria for defining hereditary prostate cancer. Both of these observations support the conclusion that the AAHPC families may be enriched for cases in which genetic factors are playing a particularly prominent role. This circumstance might be expected to be most apparent in those families with the largest number of affected cases, and so we stratified the sample into those families with 4-6 affected males, and those with 46 affected males.
Gleason scores in affected males were not different between these two groups. Overall, 77.2% of the affected men in this study demonstrated relatively favorable histology, with Gleason scores of 2-6 compared to 11% with scores of 7-10. Keetch Significantly, however, there was a marked difference between the 4-6 and 46 groups in the frequency of nodepositive disease (8.4 vs 21.7%) and distant metastases (2.1 vs 23.9%). This supports the conclusion that affected males who carry the highest load of genetic factors are at the highest risk for early dissemination of disease. That would suggest in turn that efforts at early diagnosis and aggressive therapeutic approaches may be particularly warranted in these families. Before considering that conclusion as proven, however, it is noteworthy that other researchers have reported no association between familial predisposition and clinical features or clinical course of the disease. Thus, whether hereditary prostate cancer is truly distinct from sporadic forms will probably await more accurate stratification based on discovery of the precise underlying heritable alterations. 25 Finally, it is of note that primary therapy choices in our study favored definitive treatment (87.0%) when compared to the 1983 and 1995 SEER data in which 28 and 64% received definitive treatment, respectively, 26, 27 thus suggesting that affected African-American men in multiplex families may be demonstrating the reported psychosocial impact of family history on screening practices and treatment decisions for prostate, breast, and ovarian cancer. [28] [29] [30] These men may be modifying their treatment choices based on past experience with certain practices and outcomes among other affected family members. Watchful waiting may be less attractive in men with hereditary prostate cancer, who may have had the experience of close relatives dying of metastatic disease. 21 Disparities, the National Human Genome Research
